P
Paul A. Cohen
Researcher at University of Western Australia
Publications - 106
Citations - 1573
Paul A. Cohen is an academic researcher from University of Western Australia. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 20, co-authored 94 publications receiving 1059 citations. Previous affiliations of Paul A. Cohen include Ohio State University & King Edward Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Factors influencing non-participation in an exercise program and attitudes towards physical activity amongst cancer survivors
Sarah J. Hardcastle,Chloe Maxwell-Smith,Sviatlana Kamarova,Stephanie Lamb,Lesley Millar,Paul A. Cohen,Paul A. Cohen,Paul A. Cohen +7 more
TL;DR: Seven main themes emerged: availability of the program; access, time and cost; lack of motivation or confidence; unwell or fatigued; physical activity preferences; knowledge of physical activity guidelines; and lack of referral or advice.
Journal ArticleDOI
Knowledge, attitudes, and practice of oncologists and oncology health care providers in promoting physical activity to cancer survivors: An international survey
Sarah J. Hardcastle,Robert Kane,Paola Chivers,Dana A Hince,Andrew Dean,Dominic Higgs,Paul A. Cohen +6 more
TL;DR: Oncologists reported a modest ability to promote PA, low PA promotion rates, and limited knowledge of exercise prescription; patient physical activity promotion may be improved through strategies that increase oncologists’ PBC, confidence, and their own personal PA participation.
Journal ArticleDOI
Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening
Paul A. Cohen,Paul A. Cohen,Paul A. Cohen,Nicola Flowers,Stephen Tong,Stephen Tong,Natalie J. Hannan,Natalie J. Hannan,Mark D. Pertile,Lisa Hui +9 more
TL;DR: The findings demonstrate the potential of a high throughput sequencing platform to screen for early HGSOC in plasma based on characteristic multiple segmental chromosome gains and losses.
Journal ArticleDOI
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
Dale W. Garsed,Dale W. Garsed,Kathryn Alsop,Sian Fereday,Catherine Emmanuel,Catherine Emmanuel,Catherine J. Kennedy,Dariush Etemadmoghadam,Dariush Etemadmoghadam,Bo Gao,Val Gebski,Valérie Garès,Elizabeth L. Christie,Elizabeth L. Christie,Maartje C.A. Wouters,Katy Milne,Joshy George,Ann-Marie Patch,Jason Li,Jason Li,Gisela Mir Arnau,Timothy Semple,Sreeja R. Gadipally,Yoke-Eng Chiew,Joy Hendley,Thomas Mikeska,Thomas Mikeska,Giada V. Zapparoli,Giada V. Zapparoli,Kaushalya C. Amarasinghe,Sean M. Grimmond,John V. Pearson,Nicola Waddell,Jillian Hung,Colin J.R. Stewart,Raghwa Sharma,Raghwa Sharma,Prue E. Allan,Peter F Rambau,Orla McNally,Orla McNally,Linda Mileshkin,Linda Mileshkin,Anne Hamilton,Anne Hamilton,Anne Hamilton,Sumitra Ananda,Sumitra Ananda,Marisa Grossi,Paul A. Cohen,Paul A. Cohen,Paul A. Cohen,Yee Leung,Robert M. Rome,Philip Beale,Penny Blomfield,Michael Friedlander,Alison Brand,Alison Brand,Alexander Dobrovic,Alexander Dobrovic,Alexander Dobrovic,Martin Köbel,Paul R. Harnett,Paul R. Harnett,Brad H. Nelson,David D.L. Bowtell,Anna deFazio,Anna deFazio +68 more
TL;DR: There was diversity in the clinical trajectory of exceptional survivors associated with multiple molecular determinants of exceptional outcome in HGSC patients, suggesting that co-occurrence of specific mutations might mediate durable responses in such patients.
Journal ArticleDOI
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
Paul A. Cohen,Aime Powell,Steffen Böhm,C Blake Gilks,Colin J.R. Stewart,Tarek Meniawy,Max Bulsara,Stefanie Avril,Eleanor C Brockbank,Tjalling Bosse,Gustavo Rubino de Azevedo Focchi,Raji Ganesan,Rosalind Glasspool,Brooke E. Howitt,Hyun Soo Kim,Jung Yun Lee,Nhu D. Le,Michelle Lockley,Ranjit Manchanda,Trupti Mandalia,W. Glenn McCluggage,Iain A. McNeish,Divya Midha,Radhika Srinivasan,Yun Yi Tan,Rachael van der Griend,Mayu Yunokawa,Gian Franco Zannoni,Naveena Singh +28 more
TL;DR: In this paper, the authors conducted a systematic review and meta-analysis to determine whether the chemotherapy response score (CRS) is prognostic in women with tubo-ovarian high grade serous carcinoma (HGSC) treated with NACT.